Stifel cuts AeroVironment stock price target on capex rise

AeroVironment beat Q4 FY2026 estimates with revenue of $642M (+31% organic) vs $566M/St $556M, and adjusted EPS of $1.84 vs $1.43 (Stifel) and $1.46 (Street). The company guided FY2027 revenue to $2.125B–$2.225B (~10% organic growth) with adjusted EBITDA of $305M–$325M and EPS $3.02–$3.34, but flagged ~5% headwinds each from the canceled SCAR program and Ukraine roll-off plus a delayed defense budget. Despite the results, Stifel cut its price target to $220 from $315 (still Buy) and the stock is down 51% over the past year, near the 52-week low.

Analysis

AVAV is screening like a classic “good quarter, bad stock” setup, but the real issue is not revenue momentum — it is whether the market will pay up for growth that is increasingly capital intensive and politically lumpy. The step-up in investment spending means next year’s EBITDA will overstate cash generation, so the valuation debate should shift from earnings momentum to free-cash-flow conversion; that is a headwind for rerating even if the top line keeps compounding.

The second-order winner is the broader autonomous munitions / attritable systems ecosystem: companies supplying sensors, batteries, propulsion, and battlefield networking should benefit if defense buyers keep reallocating dollars away from slower-turn legacy platforms. The loser set is more subtle — large primes that rely on fixed-budget, slow-cycle programs may see share diverted toward lower-cost, faster-fielded systems. The near-term risk is that the guidance headwinds become a narrative anchor for 1-3 months, especially if budget timing slips again and the market decides the recent growth is partly a front-loaded catch-up rather than a durable run-rate.

Contrarian view: the sell-side may be underappreciating how much of the category is still in early penetration, so a delayed budget does not necessarily kill demand, it just defers it. The bigger miss may be that consensus is still valuing AVAV like a high-growth software asset, when the operating model is closer to an industrial platform with lumpy procurement and heavy reinvestment. That argues for waiting for proof that incremental capex translates into sustained margin expansion and backlog conversion before calling this a clean multi-year rerate.

Key Decisions for Investors

• Tactically long AVAV on weakness in the $135-$145 area for a 3-6 month trade; initial upside target $175-$190, with the thesis invalidated if the stock loses the 52-week low and management cannot stabilize FY27 order visibility.
• Pair trade: long AVAV / short LMT or NOC for 1-3 months to express a rotation from legacy platforms to autonomous systems; this works only if defense dollars reallocate faster than budget delays compress the whole sector.
• Avoid chasing the print after a beat — wait for the first post-earnings pullback or analyst-driven downdraft, because the market is likely to focus on capex and budget timing before it rewards the growth mix.
• Set a watch item on FY27 free-cash-flow guidance and capex execution; if revenue growth stays >10% but cash conversion deteriorates materially, reduce exposure because the multiple could compress despite top-line strength.